KEGG   DRUG: Atoltivimab, maftivimab and odesivimab
Entry
D11922            Mixture   Drug                                   
Name
Atoltivimab, maftivimab and odesivimab;
atoltivimab, maftivimab, and odesivimab-ebgn;
Inmazeb (TN)
Product
INMAZEB (Regeneron Pharmaceuticals)
Component
Atoltivimab [DR:D11468], Maftivimab [DR:D11450], odesivimab [DR:D11921]
Remark
Product: D11922<US>
Efficacy
Antiviral
  Disease
Zaire ebolavirus infection [DS:H00283]
  Type
Monoclonal antibody, combination
Target
Zaire ebolavirus glycoprotein [KO:K24534]
  Pathway
ko03230  Viral genome structure
Brite
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Ebolavirus glycoprotein
    D11922  Atoltivimab, maftivimab and odesivimab <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11922
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11922

» Japanese version   » Back

  All links  
Ontology (3)   
   KEGG BRITE (3)   
Disease (1)   
   KEGG DISEASE (1)   
Gene (1)   
   KEGG ORTHOLOGY (1)   
All databases (5)   

Download RDF
DBGET integrated database retrieval system